Antidepressive antipsychotics Review article
Article Sidebar
Main Article Content
Abstract
Second generation antipsychotics (SGAs), especially quetiapine and olanzapine, have clearly demonstrated efficacy in the treatment of depression both in unipolar and bipolar patients. Quetiapine became the first SGA registered in the treatment of unipolar depression. This comprehensive review provides an overview of the clinical trial data of SGAs for treating depressive episodes and pharmacological issues raised in the use of SGA therapy in clinical practice.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Łoza B. Pozarejestracyjne zastosowanie leków psychotropowych. Neuropsychiatria. Przegląd Kliniczny 2012; 4(1): 5-10.
3. Buna M. Pozarejestracyjne zastosowanie kwetiapiny w leczeniu bezsenności. Neuropsychiatra. Przegląd Kliniczny 2012; 4(4): 178-181.
4. Cerullo MA, Strakowski SM. A systematic review of the evidence for the treatment of acute depression in bipolar I disorder. CNS Spectr 2013; 18(4): 199-208.
5. Łoza B, Broma J. Refractory depression treated with clozapine. Int J Neuropsychopharmacol 2004; 7: 354.
6. Tohen M, Katagiri H, Fujikoshi S et al. Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies. J Affect Disord 2013; 149(1-3): 196-201.
7. Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68(2): 224-236.
8. Łoza B. Vademecum kwetiapiny. Neuropsychiatria. Przegląd Kliniczny 2013; 5(2): 103-111.
9. Bauer M, Pretorius HW, Earley W et al. Results from a phase III study of extended release quetiapine fumarate (quetiapine XR) as add-on to antidepressants in patients with major depressive disorder (MDD). International Forum on Mood and Anxiety Disorders, Budapeszt, Węgry, 5–7 grudnia 2007.
10. Montgomery S et al. A randomised, placebo-controlled study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). International Forum on Mood and Anxiety Disorders, Budapeszt, Węgry, 5–7 grudnia 2007.
11. Tohen M, Calabrese J, Vieta E et al. Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord 2007; 104(1-3): 137-146.
12. McElroy SL, Weisler RH, Chang W et al.; EMBOLDEN II Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71(2): 163-174.
13. Croxtall JD, Scott LJ. Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs 2010; 24(3): 245-262.
14. Citrome L, Ketter TA, Cucchiaro J et al. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2014; 155: 20-27.